Increase in Fe3+/Fe2+ ratio and iron-induced oxidative stress in Eales disease and presence of ferrous iron in circulating transferrin.

Eales disease was shown to be associated with oxidant stress and weak antioxidant defense. Total iron, ferrous iron, thiobarbituric acid reactive substances (TBARS), and ceruloplasmin were estimated in the blood samples of patients with inflammation, perivasculitis, and venous insufficiency. Levels of ferric iron were determined from the difference in those of total iron and ferrous iron.

Glycation and glycoxidation studies in vitro on isolated human vitreous collagen.

Background: Structural and functional impairment in vitreous collagen plays an important role in the pathogenesis of diabetic retinopathy. Collagen being a long-lived protein is prone to both glycation and glycoxidation, resulting in accumulation of advanced glycation end products (AGE). The objective of our study was to explore the extent of glycation by glucose, and iron- and copper-mediated glycoxidation of human vitreous collagen, and also to study the beneficial effects of lysine, inositol and aminoguanidine as antiglycating and anti-cross linking agents.

Presence of a 88 kDa Eales protein in uveitis, tuberculosis, leprosy and rheumatoid arthritis.

Background: Eales disease (ED) is an idiopathic retinal vasculitis affecting young adult males. We have earlier reported the identification, purification and partial characterization of a novel 88 kDa protein found in the serum of patients with ED. The aim of the present study was to look for the 88 kDa protein in serum samples obtained from cases of retinal vasculitis mimicking ED and in other systemic inflammatory diseases.

Effect of oral supplementation of free amino acids in type 2 diabetic patients-- a pilot clinical trial.

Background: Oral amino acid intake reduces plasma glucose in Streptozotocin-induced diabetic rats. This study examined the effect of oral amino acid supplementation in patients with type 2 diabetes mellitus (DM).

Material/methods: A double blind pilot clinical trial was conducted for a period of 2 months on 77 subjects with type 2 DM.